Upper Gastrointestinal (GI) Series Market – Global Industry Analysis and Forecast (2023-2029)


Upper Gastrointestinal (GI) Series Market is expected to grow at a CAGR of 4.76% during the forecast period. Global Upper Gastrointestinal (GI) Series Market is expected to reach US$ 3.42 Bn. by 2029.

Upper Gastrointestinal (GI) Series MarketTo know about the Research Methodology :- Request Free Sample Report

Upper Gastrointestinal (GI) Series Market Definition:

An Upper Gastrointestinal (GI) is a Series of X-rays visualizing the esophagus, stomach, and small intestine after the patient swallow a chalky substance barium solution. A barium swallow is an outpatient procedure is commonly used to determine the cause of pain, swallowing problems, blood stained vomit, and unexplained weight loss that does not require sedation or anesthesia. Approximately 60-70 million people are by major and minor GI disease or disorder.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Upper Gastrointestinal (GI) Series Market: Market Dynamics:

In the report, under the Market Dynamics Global Upper Gastrointestinal (GI) Series Market covers the exhaustive study and analysis on market size, growth, drivers, restraints, challenges and opportunities faced by the industry. The complete information is based on the qualitative and quantitative assessment through interviews, survey, latest industry news, opportunities, and trends.

The global GI services market is driven by changing lifestyle, hospitalization because of the increasing occurrence of GI diseases and gastric cancer, increasing healthcare agencies expenditure and cost-effective method have also subsidized to the growth of the market. Moreover, Growing geriatric population, and increasing government support for the R&D in the market have also affected the growth positively. Each year, more than 100 million people are diagnosed with a GI disorder, resulting in 200 million sick days, 50 million medical visits, 16.9 million days lost from school, 10 million hospitalizations and nearly 200,000 deaths per year

However, limited applications of the treatment availability of alternative therapies, the side effect of drugs, lack of awareness regarding treatment in rural areas are some of the factors likely to hamper the growth of the Global Upper Gastrointestinal (GI) Series Market. The global GI series market is expected to grow at a CAGR of 5.4% during the forecasted period 2020-2027

Upper Gastrointestinal (GI) Series Market Key Trends and Opportunities Impacting Market Growth:

• Despite having the largest therapeutic areas, many of the (GI) disorder are not well understood and which gives less optimally treatment. Hence, giving Opportunities for development of new, innovative and more cost-effective treatments.

• Gastroenterology market is set to expand because of the growing population and increasing pharmaceutical companies that recognize the necessity and significance of developing innovative treatments and advancement of Research and development in Upper Gastrointestinal.

• Gastrointestinal Clinical trials activities conducted by Agency, such as FDA, National Gastrointestinal Foundation, in developing newly diagnosed medicines for gastrointestinal disease.

Global Upper Gastrointestinal (GI) Series Market: Market Segmentation:

The report covers the comprehensive analytical segments of the Upper Gastrointestinal (GI) Series Market thereby providing a brief insight into the small and large sector. Esophageal reflux is projected to dominate the largest market at the CAGR of XX %. By application esophageal reflux commonly known as acid reflux one of the largest sub-segments of the GI market. Individual go through persistent acid reflux that is more than twice a week and features by a burning pain, also known as heartburn Proton pump inhibitors are the main pharmaceutical treatment. Regularly More than 60 million Americans are supposed to have acid reflux, causing to frequent hospital admittances. GERD is common in western countries affecting 20-30% population. Up to 10% of patients nearly five million complaints of recurrent pain and heartburn. Followed by irritable bowel syndrome (IBS) and dyspepsia.

Based on end-user, Hospitals dominates the largest market during the forecast growth of the market. Hospitals ensuring hygiene and maintaining the clinical trial for safety and efficacy with monitoring health benefit delivers complete treatment and providing professionals care immediately. Along with, surgical services and Approach of 24/7 service. The preliminary examination is adopted effectively improving the quality of life.

Upper Gastrointestinal (GI) Series Market: Regional analysis

In terms of region, North America dominant the Global Upper Gastrointestinal (GI) Series Market and was valued at US$ xx Bn in 2019 and is expected to reach a value of US$ xx Bn by 2029, with a CAGR of xx% during the forecast period. The major factors dominating the growth of Global Upper Gastrointestinal (GI) Series Market are existences of well-developed health care agencies and drugs available for the treatment of Global Upper Gastrointestinal in the region with large people suffering for chronic disorder and growing geriatric population. The occurrence rate in adults aged is nearly 60 to 70 besides the only, in the U.S about 20% of people have symptoms every week almost 7% every day. Furthermore, 80 million people worldwide about 24 million of whom live in Europe, suffer from constipation.

Upper Gastrointestinal (GI) Series Market Competitive Analysis:

Global Upper Gastrointestinal (GI) is a competitive market as large companies are investing in R&D to launch new products in a cost-effective manner to provides a valuable insight of industry statements of Market and various strategies such as collaborations, expansions, acquisitions, and portfolio, joint ventures, and Cancer to put down the other competitor.

Eisai Co., Ltd. company announced its partnership with AJINOMOTO CO.,INC. for the formation of gastrointestinal EA Pharma Co., Ltd. and has launched product used for contrast media. &nbsp.

GE Healthcare one of the leading American multinational company in the U.S. Recently company has launch Clariscan, which is a macrocyclic agent and use for effective visualization for abnormalities in the brain, spine and associated tissues. OMNISCAN and VISIPAQUE are the major products.

The objective of the report is to present a comprehensive analysis of the Upper Gastrointestinal (GI) Series Market including all the stakeholders of the industry. The past and current status of the industry with forecasted Market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes Market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the Market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Upper Gastrointestinal (GI) Series Market dynamics, structure by analyzing the Market segments and projects the Upper Gastrointestinal (GI) Series Market size. Clear representation of competitive analysis of key players By Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Upper Gastrointestinal (GI) Series Market make the report investor’s guide

Scope of the Global Upper Gastrointestinal (GI) Series Market : Inquire before buying






Global Upper Gastrointestinal (GI) Series Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2017 to 2022
Market Size in 2022:
US $ 2.47 Bn.




Forecast Period 2023 to 2029 CAGR:
4.76%
Market Size in 2029:
US $ 3.42 Bn.




 Segments Covered:
by Test Type
• Standard barium upper GI series
• Double-contrast upper GI series




by Application
• Hiatal hernias
• Ulcers
• Tumors
• Esophageal varices
• Esophageal reflux
• Strictures
• Enteritis
• Gastrointestinal dysmotility
• Cancer




by End User
• Hospitals
• Laboratories
• Clinics






Upper Gastrointestinal (GI) Series Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina, Columbia and Rest of South America)

Upper Gastrointestinal (GI) Series Market, Key Players are:

• GastroIntestinal Endoscopy
• GastroIntestinal Specialists
• Eisai US
• Cadila Pharmaceuticals Limited
• PeaceHealth
• Purdue Pharma L.P.
• Alfa Wassermann
• NOVADAQ
• Mount Sinai Beth Israel
• AstraZeneca
• Ironwood Pharmaceuticals
• GE, Healthcare
• Outpost Medicine
• Cook Group
• Frequency Therapeutics
• Ardelyx
• Meridian Bioscience Inc
• Second Genome
• Arena Pharmaceuticals, Inc
• APC Microbiome Institute

Frequently Asked Questions:

1. Which region has the largest share in Global Upper Gastrointestinal (GI) Series Market ?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Upper Gastrointestinal (GI) Series Market ?
Ans: The Global Upper Gastrointestinal (GI) Series Market is growing at a CAGR of 4.76% during forecasting period 2023-2029.

3. What is scope of the Global Upper Gastrointestinal (GI) Series Market report?
Ans: Global Upper Gastrointestinal (GI) Series Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Upper Gastrointestinal (GI) Series Market ?
Ans: The important key players in the Global Upper Gastrointestinal (GI) Series Market are – GastroIntestinal Endoscopy, GastroIntestinal Specialists, Eisai US, Cadila Pharmaceuticals Limited, PeaceHealth, Purdue Pharma L.P., Alfa Wassermann, NOVADAQ, Mount Sinai Beth Israel, AstraZeneca, Ironwood Pharmaceuticals, GE, Healthcare, Outpost Medicine, Cook Group, Frequency Therapeutics, Ardelyx, Meridian Bioscience Inc, Second Genome, Arena Pharmaceuticals, Inc, APC Microbiome Institute.

5. What is the study period of this Market?
Ans: The Global Upper Gastrointestinal (GI) Series Market is studied from 2023 to 2029. 




Global Upper Gastrointestinal (GI) Series Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Upper Gastrointestinal (GI) Series Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Upper Gastrointestinal (GI) Series Market Analysis and Forecast
6.1. Global Upper Gastrointestinal (GI) Series Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Upper Gastrointestinal (GI) Series Market Analysis and Forecast, By Test Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type
7.4. Global Upper Gastrointestinal (GI) Series Market Size (US$ Bn) Forecast, By Test Type
7.5. Global Upper Gastrointestinal (GI) Series Market Analysis, By Test Type
7.6. Global Upper Gastrointestinal (GI) Series Market Attractiveness Analysis, By Test Type

8. Global Upper Gastrointestinal (GI) Series Market Analysis and Forecast, By Application
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application
8.4. Global Upper Gastrointestinal (GI) Series Market Size (US$ Bn) Forecast, By Application
8.5. Global Upper Gastrointestinal (GI) Series Market Analysis, By Application
8.6. Global Upper Gastrointestinal (GI) Series Market Attractiveness Analysis, By Application

9. Global Upper Gastrointestinal (GI) Series Market Analysis and Forecast, By End-Users
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users
9.4. Global Upper Gastrointestinal (GI) Series Market Size (US$ Bn) Forecast, By End-Users
9.5. Global Upper Gastrointestinal (GI) Series Market Analysis, By End-Users
9.6. Global Upper Gastrointestinal (GI) Series Market Attractiveness Analysis, By End-Users

10. Global Upper Gastrointestinal (GI) Series Market Analysis, by Region
10.1. Global Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Region
10.2. Global Upper Gastrointestinal (GI) Series Market Size (US$ Bn) Forecast, by Region
10.3. Global Upper Gastrointestinal (GI) Series Market Attractiveness Analysis, by Region

11. North America Upper Gastrointestinal (GI) Series Market Analysis
11.1. Key Findings
11.2. North America Upper Gastrointestinal (GI) Series Market Overview
11.3. North America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type
11.4. North America Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
11.4.1. Standard barium upper GI series
11.4.2. Double-contrast upper GI series
11.5. North America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application
11.6. North America Upper Gastrointestinal (GI) Series Market Forecast, By Application
11.6.1. Hiatal hernias
11.6.2. Ulcers
11.6.3. Tumors
11.6.4. Esophageal varices
11.6.5. Esophageal reflux
11.6.6. Strictures
11.6.7. Enteritis
11.6.8. Gastrointestinal dysmotility
11.6.9. Cancer
11.7. North America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users
11.8. North America Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
11.8.1. Hospitals
11.8.2. Laboratories
11.8.3. Clinics
11.9. North America Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country
11.10. North America Upper Gastrointestinal (GI) Series Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Upper Gastrointestinal (GI) Series Market Analysis, by Country
11.12. U.S. Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
11.12.1. Standard barium upper GI series
11.12.2. Double-contrast upper GI series
11.13. U.S. Upper Gastrointestinal (GI) Series Market Forecast, By Application
11.13.1. Hiatal hernias
11.13.2. Ulcers
11.13.3. Tumors
11.13.4. Esophageal varices
11.13.5. Esophageal reflux
11.13.6. Strictures
11.13.7. Enteritis
11.13.8. Gastrointestinal dysmotility
11.13.9. Cancer
11.14. U.S. Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
11.14.1. Hospitals
11.14.2. Laboratories
11.14.3. Clinics
11.15. Canada Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
11.15.1. Standard barium upper GI series
11.15.2. Double-contrast upper GI series
11.16. Canada Upper Gastrointestinal (GI) Series Market Forecast, By Application
11.16.1. Hiatal hernias
11.16.2. Ulcers
11.16.3. Tumors
11.16.4. Esophageal varices
11.16.5. Esophageal reflux
11.16.6. Strictures
11.16.7. Enteritis
11.16.8. Gastrointestinal dysmotility
11.16.9. Cancer
11.17. Canada Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
11.17.1. Hospitals
11.17.2. Laboratories
11.17.3. Clinics
11.18. North America Upper Gastrointestinal (GI) Series Market Attractiveness Analysis
11.18.1. By Test Type
11.18.2. By Application
11.18.3. By End-Users
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Upper Gastrointestinal (GI) Series Market Analysis
12.1. Key Findings
12.2. Europe Upper Gastrointestinal (GI) Series Market Overview
12.3. Europe Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type
12.4. Europe Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
12.4.1. Standard barium upper GI series
12.4.2. Double-contrast upper GI series
12.5. Europe Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application
12.6. Europe Upper Gastrointestinal (GI) Series Market Forecast, By Application
12.6.1. Hiatal hernias
12.6.2. Ulcers
12.6.3. Tumors
12.6.4. Esophageal varices
12.6.5. Esophageal reflux
12.6.6. Strictures
12.6.7. Enteritis
12.6.8. Gastrointestinal dysmotility
12.6.9. Cancer
12.7. Europe Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users
12.8. Europe Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
12.8.1. Hospitals
12.8.2. Laboratories
12.8.3. Clinics
12.9. Europe Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country
12.10. Europe Upper Gastrointestinal (GI) Series Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Upper Gastrointestinal (GI) Series Market Analysis, by Country
12.12. Germany Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
12.12.1. Standard barium upper GI series
12.12.2. Double-contrast upper GI series
12.13. Germany Upper Gastrointestinal (GI) Series Market Forecast, By Application
12.13.1. Hiatal hernias
12.13.2. Ulcers
12.13.3. Tumors
12.13.4. Esophageal varices
12.13.5. Esophageal reflux
12.13.6. Strictures
12.13.7. Enteritis
12.13.8. Gastrointestinal dysmotility
12.13.9. Cancer
12.14. Germany Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
12.14.1. Hospitals
12.14.2. Laboratories
12.14.3. Clinics
12.15. U.K. Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
12.15.1. Standard barium upper GI series
12.15.2. Double-contrast upper GI series
12.16. U.K. Upper Gastrointestinal (GI) Series Market Forecast, By Application
12.16.1. Hiatal hernias
12.16.2. Ulcers
12.16.3. Tumors
12.16.4. Esophageal varices
12.16.5. Esophageal reflux
12.16.6. Strictures
12.16.7. Enteritis
12.16.8. Gastrointestinal dysmotility
12.16.9. Cancer
12.17. U.K. Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
12.17.1. Hospitals
12.17.2. Laboratories
12.17.3. Clinics
12.18. France Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
12.18.1. Standard barium upper GI series
12.18.2. Double-contrast upper GI series
12.19. France Upper Gastrointestinal (GI) Series Market Forecast, By Application
12.19.1. Hiatal hernias
12.19.2. Ulcers
12.19.3. Tumors
12.19.4. Esophageal varices
12.19.5. Esophageal reflux
12.19.6. Strictures
12.19.7. Enteritis
12.19.8. Gastrointestinal dysmotility
12.19.9. Cancer
12.20. France Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
12.20.1. Hospitals
12.20.2. Laboratories
12.20.3. Clinics
12.21. Italy Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
12.21.1. Standard barium upper GI series
12.21.2. Double-contrast upper GI series
12.22. Italy Upper Gastrointestinal (GI) Series Market Forecast, By Application
12.22.1. Hiatal hernias
12.22.2. Ulcers
12.22.3. Tumors
12.22.4. Esophageal varices
12.22.5. Esophageal reflux
12.22.6. Strictures
12.22.7. Enteritis
12.22.8. Gastrointestinal dysmotility
12.22.9. Cancer
12.23. Italy Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
12.23.1. Hospitals
12.23.2. Laboratories
12.23.3. Clinics
12.24. Spain Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
12.24.1. Standard barium upper GI series
12.24.2. Double-contrast upper GI series
12.25. Spain Upper Gastrointestinal (GI) Series Market Forecast, By Application
12.25.1. Hiatal hernias
12.25.2. Ulcers
12.25.3. Tumors
12.25.4. Esophageal varices
12.25.5. Esophageal reflux
12.25.6. Strictures
12.25.7. Enteritis
12.25.8. Gastrointestinal dysmotility
12.25.9. Cancer
12.26. Spain Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
12.26.1. Hospitals
12.26.2. Laboratories
12.26.3. Clinics
12.27. Rest of Europe Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
12.27.1. Standard barium upper GI series
12.27.2. Double-contrast upper GI series
12.28. Rest of Europe Upper Gastrointestinal (GI) Series Market Forecast, By Application
12.28.1. Hiatal hernias
12.28.2. Ulcers
12.28.3. Tumors
12.28.4. Esophageal varices
12.28.5. Esophageal reflux
12.28.6. Strictures
12.28.7. Enteritis
12.28.8. Gastrointestinal dysmotility
12.28.9. Cancer
12.29. Rest Of Europe Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
12.29.1. Hospitals
12.29.2. Laboratories
12.29.3. Clinics
12.30. Europe Upper Gastrointestinal (GI) Series Market Attractiveness Analysis
12.30.1. By Test Type
12.30.2. By Application
12.30.3. By End-Users
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Upper Gastrointestinal (GI) Series Market Analysis
13.1. Key Findings
13.2. Asia Pacific Upper Gastrointestinal (GI) Series Market Overview
13.3. Asia Pacific Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type
13.4. Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
13.4.1. Standard barium upper GI series
13.4.2. Double-contrast upper GI series
13.5. Asia Pacific Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application
13.6. Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By Application
13.6.1. Hiatal hernias
13.6.2. Ulcers
13.6.3. Tumors
13.6.4. Esophageal varices
13.6.5. Esophageal reflux
13.6.6. Strictures
13.6.7. Enteritis
13.6.8. Gastrointestinal dysmotility
13.6.9. Cancer
13.7. Asia Pacific Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users
13.8. Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
13.8.1. Hospitals
13.8.2. Laboratories
13.8.3. Clinics
13.9. Asia Pacific Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country
13.10. Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Upper Gastrointestinal (GI) Series Market Analysis, by Country
13.12. China Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
13.12.1. Standard barium upper GI series
13.12.2. Double-contrast upper GI series
13.13. China Upper Gastrointestinal (GI) Series Market Forecast, By Application
13.13.1. Hiatal hernias
13.13.2. Ulcers
13.13.3. Tumors
13.13.4. Esophageal varices
13.13.5. Esophageal reflux
13.13.6. Strictures
13.13.7. Enteritis
13.13.8. Gastrointestinal dysmotility
13.13.9. Cancer
13.14. China Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
13.14.1. Hospitals
13.14.2. Laboratories
13.14.3. Clinics
13.15. India Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
13.15.1. Standard barium upper GI series
13.15.2. Double-contrast upper GI series
13.16. India Upper Gastrointestinal (GI) Series Market Forecast, By Application
13.16.1. Hiatal hernias
13.16.2. Ulcers
13.16.3. Tumors
13.16.4. Esophageal varices
13.16.5. Esophageal reflux
13.16.6. Strictures
13.16.7. Enteritis
13.16.8. Gastrointestinal dysmotility
13.16.9. Cancer
13.17. India Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
13.17.1. Hospitals
13.17.2. Laboratories
13.17.3. Clinics
13.18. Japan Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
13.18.1. Standard barium upper GI series
13.18.2. Double-contrast upper GI series
13.19. Japan Upper Gastrointestinal (GI) Series Market Forecast, By Application
13.19.1. Hiatal hernias
13.19.2. Ulcers
13.19.3. Tumors
13.19.4. Esophageal varices
13.19.5. Esophageal reflux
13.19.6. Strictures
13.19.7. Enteritis
13.19.8. Gastrointestinal dysmotility
13.19.9. Cancer
13.20. Japan Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
13.20.1. Hospitals
13.20.2. Laboratories
13.20.3. Clinics
13.21. ASEAN Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
13.21.1. Standard barium upper GI series
13.21.2. Double-contrast upper GI series
13.22. ASEAN Upper Gastrointestinal (GI) Series Market Forecast, By Application
13.22.1. Hiatal hernias
13.22.2. Ulcers
13.22.3. Tumors
13.22.4. Esophageal varices
13.22.5. Esophageal reflux
13.22.6. Strictures
13.22.7. Enteritis
13.22.8. Gastrointestinal dysmotility
13.22.9. Cancer
13.23. ASEAN Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
13.23.1. Hospitals
13.23.2. Laboratories
13.23.3. Clinics
13.24. Rest of Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
13.24.1. Standard barium upper GI series
13.24.2. Double-contrast upper GI series
13.25. Rest of Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By Application
13.25.1. Hiatal hernias
13.25.2. Ulcers
13.25.3. Tumors
13.25.4. Esophageal varices
13.25.5. Esophageal reflux
13.25.6. Strictures
13.25.7. Enteritis
13.25.8. Gastrointestinal dysmotility
13.25.9. Cancer
13.26. Rest of Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
13.26.1. Hospitals
13.26.2. Laboratories
13.26.3. Clinics
13.27. Asia Pacific Upper Gastrointestinal (GI) Series Market Attractiveness Analysis
13.27.1. By Test Type
13.27.2. By Application
13.27.3. By End-Users
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Upper Gastrointestinal (GI) Series Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Upper Gastrointestinal (GI) Series Market Overview
14.3. Middle East & Africa Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type
14.4. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
14.4.1. Standard barium upper GI series
14.4.2. Double-contrast upper GI series
14.5. Middle East & Africa Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application
14.6. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By Application
14.6.1. Hiatal hernias
14.6.2. Ulcers
14.6.3. Tumors
14.6.4. Esophageal varices
14.6.5. Esophageal reflux
14.6.6. Strictures
14.6.7. Enteritis
14.6.8. Gastrointestinal dysmotility
14.6.9. Cancer
14.7. Middle East & Africa Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users
14.8. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
14.8.1. Hospitals
14.8.2. Laboratories
14.8.3. Clinics
14.9. Middle East & Africa Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country
14.10. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Upper Gastrointestinal (GI) Series Market Analysis, by Country
14.12. GCC Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
14.12.1. Standard barium upper GI series
14.12.2. Double-contrast upper GI series
14.13. GCC Upper Gastrointestinal (GI) Series Market Forecast, By Application
14.13.1. Hiatal hernias
14.13.2. Ulcers
14.13.3. Tumors
14.13.4. Esophageal varices
14.13.5. Esophageal reflux
14.13.6. Strictures
14.13.7. Enteritis
14.13.8. Gastrointestinal dysmotility
14.13.9. Cancer
14.14. GCC Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
14.14.1. Hospitals
14.14.2. Laboratories
14.14.3. Clinics
14.15. South Africa Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
14.15.1. Standard barium upper GI series
14.15.2. Double-contrast upper GI series
14.16. South Africa Upper Gastrointestinal (GI) Series Market Forecast, By Application
14.16.1. Hiatal hernias
14.16.2. Ulcers
14.16.3. Tumors
14.16.4. Esophageal varices
14.16.5. Esophageal reflux
14.16.6. Strictures
14.16.7. Enteritis
14.16.8. Gastrointestinal dysmotility
14.16.9. Cancer
14.17. South Africa Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
14.17.1. Hospitals
14.17.2. Laboratories
14.17.3. Clinics
14.18. Rest of Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
14.18.1. Standard barium upper GI series
14.18.2. Double-contrast upper GI series
14.19. Rest of Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By Application
14.19.1. Hiatal hernias
14.19.2. Ulcers
14.19.3. Tumors
14.19.4. Esophageal varices
14.19.5. Esophageal reflux
14.19.6. Strictures
14.19.7. Enteritis
14.19.8. Gastrointestinal dysmotility
14.19.9. Cancer
14.20. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
14.20.1. Hospitals
14.20.2. Laboratories
14.20.3. Clinics
14.21. Middle East & Africa Upper Gastrointestinal (GI) Series Market Attractiveness Analysis
14.21.1. By Test Type
14.21.2. By Application
14.21.3. By End-Users
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Upper Gastrointestinal (GI) Series Market Analysis
15.1. Key Findings
15.2. South America Upper Gastrointestinal (GI) Series Market Overview
15.3. South America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type
15.4. South America Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
15.4.1. Standard barium upper GI series
15.4.2. Double-contrast upper GI series
15.5. South America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application
15.6. South America Upper Gastrointestinal (GI) Series Market Forecast, By Application
15.6.1. Hiatal hernias
15.6.2. Ulcers
15.6.3. Tumors
15.6.4. Esophageal varices
15.6.5. Esophageal reflux
15.6.6. Strictures
15.6.7. Enteritis
15.6.8. Gastrointestinal dysmotility
15.6.9. Cancer
15.7. South America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users
15.8. South America Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
15.8.1. Hospitals
15.8.2. Laboratories
15.8.3. Clinics
15.9. South America Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country
15.10. South America Upper Gastrointestinal (GI) Series Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Upper Gastrointestinal (GI) Series Market Analysis, by Country
15.12. Brazil Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
15.12.1. Standard barium upper GI series
15.12.2. Double-contrast upper GI series
15.13. Brazil Upper Gastrointestinal (GI) Series Market Forecast, By Application
15.13.1. Hiatal hernias
15.13.2. Ulcers
15.13.3. Tumors
15.13.4. Esophageal varices
15.13.5. Esophageal reflux
15.13.6. Strictures
15.13.7. Enteritis
15.13.8. Gastrointestinal dysmotility
15.13.9. Cancer
15.14. Brazil Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
15.14.1. Hospitals
15.14.2. Laboratories
15.14.3. Clinics
15.15. Mexico Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
15.15.1. Standard barium upper GI series
15.15.2. Double-contrast upper GI series
15.16. Mexico Upper Gastrointestinal (GI) Series Market Forecast, By Application
15.16.1. Hiatal hernias
15.16.2. Ulcers
15.16.3. Tumors
15.16.4. Esophageal varices
15.16.5. Esophageal reflux
15.16.6. Strictures
15.16.7. Enteritis
15.16.8. Gastrointestinal dysmotility
15.16.9. Cancer
15.17. Mexico Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
15.17.1. Hospitals
15.17.2. Laboratories
15.17.3. Clinics
15.18. Rest of South America Upper Gastrointestinal (GI) Series Market Forecast, By Test Type
15.18.1. Standard barium upper GI series
15.18.2. Double-contrast upper GI series
15.19. Rest of South America Upper Gastrointestinal (GI) Series Market Forecast, By Application
15.19.1. Hiatal hernias
15.19.2. Ulcers
15.19.3. Tumors
15.19.4. Esophageal varices
15.19.5. Esophageal reflux
15.19.6. Strictures
15.19.7. Enteritis
15.19.8. Gastrointestinal dysmotility
15.19.9. Cancer
15.20. Cancer Rest of South America Upper Gastrointestinal (GI) Series Market Forecast, By End-Users
15.20.1. Hospitals
15.20.2. Laboratories
15.20.3. Clinics
15.21. South America Upper Gastrointestinal (GI) Series Market Attractiveness Analysis
15.21.1. By Test Type
15.21.2. By Application
15.21.3. By End-Users
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, Market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
16.2.3.3. Integration
16.3. Company Profiles: Key Players
16.3.1. GastroIntestinal Endoscopy
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. GastroIntestinal Specialists
16.3.3. Eisai US
16.3.4. Cadila Pharmaceuticals Limited
16.3.5. PeaceHealth
16.3.6. Purdue Pharma L.P.
16.3.7. Alfa Wassermann
16.3.8. NOVADAQ
16.3.9. Mount Sinai Beth Israel
16.3.10. AstraZeneca
16.3.11. Ironwood Pharmaceuticals
16.3.12. GE, Healthcare
16.3.13. Outpost Medicine
16.3.14. Cook Group
16.3.15. Frequency Therapeutics
16.3.16. Ardelyx
16.3.17. Meridian Bioscience Inc
16.3.18. Second Genome
16.3.19. Arena Pharmaceuticals, Inc
16.3.20. APC Microbiome Institute
17. Primary Key Insights
  • INQUIRE BEFORE BUYING